ライフサイエンスコーパス: prior authorization

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ormularies at co-payments of <or=$35 without prior authorization).

2 and there would be no issues with insurance prior authorization.

3 Cost and prior authorization affected the therapy choices of uvei

4 mine whether prescription of coxibs required prior authorization and, if so, the criteria for authori

5 nd posterior uveitis is affected by cost and prior authorization concerns, pregnancy considerations,

6 Thirty-two states required prior authorization for > or = 1 biologic DMARD, with wi

7 h has recently demonstrated that a policy of prior authorization for prescription of nonsteroidal ant

8 States that implemented prior authorization for these agents initially had lower

9 come significantly decreased from 15% in the prior-authorization group to 11% in the limited-use grou

10 ut may be attributable to the elimination of prior authorization in California during the same time f

11 d, including preferred drug/formulary lists, prior authorization, medication dosing/number limits, "f

12 hcare systems utilizing Cerner to facilitate prior authorization of antimicrobials, prospective audit

13 cardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use per

14 tates vary widely in their implementation of prior authorization policies to limit use of biologic DM

15 these proportions in states with and without prior authorization policies.

16 We obtained biologic DMARD prior authorization policy information from state Medica

17 rnment in a pharmacy-benefits program from a prior-authorization policy to a less restrictive, limite

18 d in 2015, their high cost has led to strict prior authorization practices and high copays, and use o

19 differences in therapy choice based on cost/prior authorization, pregnancy, and subspecialty practic

20 was not influenced by the degree to which a prior-authorization program incorporated evidence-based

21 The removal of a prior-authorization program led to improvement in timely

22 on patterns after the implementation of each prior-authorization program.

23 Twenty-two states implemented prior-authorization programs for coxibs during the study

24 ed substantially after the implementation of prior-authorization programs.

25 , each study site was granted exemption from prior authorization requirements by radiology benefits m

26 There were 18 states with prior authorization requirements for adalimumab or etane

27 similar to that in states that did not have prior authorization requirements.

28 any state Medicaid programs have implemented prior-authorization requirements before coxibs can be pr

29 lower deductibles, lower premiums, and fewer prior authorization, step therapy, and quantity limit re

30 e in therapy for each vignette when cost and prior authorization were equalized (P = .0018, P = .0049

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。